Home > Journals > International Angiology > Past Issues > International Angiology 2018 February;37(1) > International Angiology 2018 February;37(1):19-25

CURRENT ISSUE
 

JOURNAL TOOLS

eTOC
To subscribe
Submit an article
Recommend to your librarian
 

ARTICLE TOOLS

Publication history
Reprints
Permissions
Cite this article as

 

ORIGINAL ARTICLE   Freefree

International Angiology 2018 February;37(1):19-25

DOI: 10.23736/S0392-9590.17.03877-9

Copyright © 2017 EDIZIONI MINERVA MEDICA

language: English

Diagnostic value of circulating microRNA-27a/b in patients with acute pulmonary embolism

Qian WANG, Junfen MA, Zhiyun JIANG, Fan WU, Jiedan PING, Liang MING

Department of Clinical Laboratory, the First Affiliated Hospital of Zhengzhou University, Key Laboratory of Laboratory Medicine of Henan Province, Zhengzhou, Henan, China


PDF


BACKGROUND: Circulating microRNAs (miRNAs) have been increasingly suggested as biomarkers for numerous diseases. The aims of this study were to evaluate the expression of plasma miR-27a/b in patients with acute pulmonary embolism (APE) and determine the possibility of miR-27a/b as diagnostic biomarkers for APE.
METHODS: Seventy-eight APE patients diagnosed by computed tomographic pulmonary angiography (CTPA) and 70 age and gender matched normal volunteers were included in this study. The levels of miR-27a and miR-27b were measured by quantitative reverse transcription-polymerase chain reaction (qRT-PCR) and the concentrations of plasma D-dimer were measured using immunoturbidimetric assay.
RESULTS: The levels of plasma miR-27a and miR-27b were significantly higher in APE patients (P<0.001) compared with normal controls. Receiver operating characteristic (ROC) curve analyses showed that plasma miR-27a was superior to miR-27b for the diagnosis of APE (AUC=0.784, AUC=0.707, respectively). Combining miR-27a or miR-27b with D-dimer significantly increased the diagnostic capacity of APE.
CONCLUSIONS: Our results showed that circulating miR-27a and miR-27b might be potential novel diagnostic biomarkers in APE patients.


KEY WORDS: MicroRNAs - Pulmonary embolism - Biomarkers

top of page